0000899243-18-002333.txt : 20180130
0000899243-18-002333.hdr.sgml : 20180130
20180130210133
ACCESSION NUMBER: 0000899243-18-002333
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180126
FILED AS OF DATE: 20180130
DATE AS OF CHANGE: 20180130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shaff Eric D.
CENTRAL INDEX KEY: 0001643734
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 18560726
MAIL ADDRESS:
STREET 1: C/O SERES HEALTH, INC.
STREET 2: 161 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-26
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001643734
Shaff Eric D.
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
COMMON STOCK
2018-01-26
4
M
0
8000
A
8000
D
COMMON STOCK
2018-01-26
4
S
0
2780
11.02
D
5220
D
RESTRICTED STOCK UNITS
2018-01-26
4
M
0
8000
0.00
D
COMMON STOCK
8000
32000
D
STOCK OPTION (RIGHT TO BUY)
10.42
2018-01-30
4
A
0
120000
0.00
D
2028-01-29
COMMON STOCK
120000
120000
D
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
These restricted stock units have vested and settled or will vest and settle as to 20% of the restricted stock units on January 26, 2018, 30% on January 26, 2019; and 50% on January 26, 2020.
The Option will vest as to 25% of the shares on January 30, 2019. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Chief Financial Officer and EVP
/s/ Thomas J. DesRosier, Attorney-in-Fact
2018-01-30